amifostine anhydrous has been researched along with Breast Neoplasms in 31 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 9.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "Tamoxifen (TAM) is a non-steroidal anti-estrogen used widely in the treatment and chemoprevention of breast cancer." | 7.74 | The DNA-damaging potential of tamoxifen in breast cancer and normal cells. ( Blasiak, J; Blasinska-Morawiec, M; Kolacinska, A; Morawiec, Z; Morawiec-Bajda, A; Wozniak, K; Zadrozny, M, 2007) |
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 5.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "Tamoxifen (TAM) is a non-steroidal anti-estrogen used widely in the treatment and chemoprevention of breast cancer." | 3.74 | The DNA-damaging potential of tamoxifen in breast cancer and normal cells. ( Blasiak, J; Blasinska-Morawiec, M; Kolacinska, A; Morawiec, Z; Morawiec-Bajda, A; Wozniak, K; Zadrozny, M, 2007) |
| "Breast cancer patients receiving high-dose infusional paclitaxel (725 mg/m(2)/24 h) in combination with doxorubicin (165 mg/m(2)/96 h) and cyclophosphamide (100 mg/kg/2 h; ACT) were studied on two autologous peripheral blood stem cell transplant protocols, one with and one without amifostine (740 mg/m(2) administered over 10 min before and 12 h after initiation of the paclitaxel infusion)." | 3.72 | Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. ( Beamon, K; Doroshow, JH; Forman, S; Longmate, J; Margolin, K; Morgan, R; Openshaw, H; Shibata, S; Slatkin, NE; Somlo, G; Synold, TW, 2004) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| " Professionals discussed a novel treatment (Irinotecan) for advanced colorectal cancers; a unique anticancer agent (Docetaxel) effective in hard-to-treat head and neck cancer; a highly active neoadjuvant chemotherapy regimen for operable breast cancer; and a cytoprotective agent (Amifostine) capable of protecting normal tissue from radiation and chemotherapeutic toxicity." | 3.69 | Highlights of the Eighth European Cancer Conference. ( Prescott, LM, 1995) |
| " At baseline, before each treatment cycle, and for 3 months after completing chemotherapy, patients were evaluated for evidence of neurotoxicity and other treatment-related adverse effects using three methods: standard clinical evaluation (National Cancer Institute common toxicity criteria [CTC] grading), a neurotoxicity questionnaire to assess symptoms and limitations imposed by peripheral neuropathy, and vibration perception threshold (VPT) testing." | 2.71 | Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. ( Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE, 2003) |
| " Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e." | 2.70 | A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). ( Abeloff, MD; Glover, DJ; Gradishar, WJ; Moore, MR; Neuberg, DS; Piel, I; Stephenson, P; Windschitl, HE, 2001) |
| " We conducted a clinical and pharmacokinetic pilot study to assess the feasibility and toxicity of the docetaxel plus amifostine combination and the absence of influence of amifostine on docetaxel pharmacokinetics." | 2.70 | Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ( Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J, 2002) |
| " Thus, effective yet safe methods of radiation injury prophylaxis would be desirable." | 1.56 | Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro. ( Buchman, LK; Buchman, SR; Cohen, MS; Donneys, A; Luby, AO; Lynn, JV; Nelson, NS; Subramanian, C; Urlaub, KM, 2020) |
| "Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively." | 1.51 | Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. ( Benel, L; Bloy, C; Bricout, D; Chargari, C; Clémenson, C; Deutsch, E; Haddad, R; Liu, W; Mondini, M; Soyez-Herkert, L; Wang-Zhang, X, 2019) |
| "A cohort of 32 breast cancer patients, pretreated with conservative surgery and adjuvant doxorubicin or taxane based chemotherapy, were treated with hypoARC." | 1.33 | Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery. ( Ambatzoglou, J; Koukourakis, MI; Manavis, J; Sismanidou, K, 2006) |
| "By contrast, 60% of the tumors analyzed showed a loss of IAP expression in both epithelial cells and stroma, and only 10% to 15% of them demonstrated nuclear/cytoplasmic reactivity, which was confined to the epithelial cells." | 1.31 | Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. ( Giatromanolaki, A; Koukourakis, MI; Maltezos, E; Sivridis, E, 2002) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 8 (25.81) | 18.2507 |
| 2000's | 16 (51.61) | 29.6817 |
| 2010's | 5 (16.13) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Luby, AO | 1 |
| Subramanian, C | 1 |
| Buchman, LK | 1 |
| Lynn, JV | 1 |
| Urlaub, KM | 1 |
| Nelson, NS | 2 |
| Donneys, A | 2 |
| Cohen, MS | 1 |
| Buchman, SR | 2 |
| Clémenson, C | 1 |
| Liu, W | 1 |
| Bricout, D | 1 |
| Soyez-Herkert, L | 1 |
| Chargari, C | 1 |
| Mondini, M | 1 |
| Haddad, R | 1 |
| Wang-Zhang, X | 1 |
| Benel, L | 1 |
| Bloy, C | 1 |
| Deutsch, E | 1 |
| Polyatskaya, Y | 1 |
| Rodriguez, JJ | 1 |
| Zheutlin, AR | 1 |
| Deshpande, SS | 1 |
| Felice, PA | 1 |
| Koukourakis, MI | 9 |
| Giatromanolaki, A | 6 |
| Zois, CE | 1 |
| Kalamida, D | 1 |
| Pouliliou, S | 1 |
| Karagounis, IV | 1 |
| Yeh, TL | 1 |
| Abboud, MI | 1 |
| Claridge, TD | 1 |
| Schofield, CJ | 1 |
| Sivridis, E | 6 |
| Simopoulos, C | 2 |
| Tokmakidis, SP | 1 |
| Harris, AL | 2 |
| Tsoutsou, PG | 1 |
| Abatzoglou, IM | 2 |
| Sismanidou, K | 3 |
| Pinto, JL | 1 |
| Fonseca, FL | 1 |
| Marsicano, SR | 1 |
| Delgado, PO | 1 |
| Sant'anna, AV | 1 |
| Coelho, PG | 1 |
| Maeda, P | 1 |
| Del Giglio, A | 1 |
| Panteliadou, M | 1 |
| Maltezos, E | 1 |
| Ktenidou-Kartali, S | 1 |
| Bourikas, G | 1 |
| Kartalis, G | 1 |
| Tsatalas, C | 1 |
| Chong, W | 1 |
| Polychronidis, A | 1 |
| Moore, DH | 1 |
| Donnelly, J | 1 |
| McGuire, WP | 1 |
| Almadrones, L | 1 |
| Cella, DF | 1 |
| Herzog, TJ | 1 |
| Waggoner, SE | 1 |
| Openshaw, H | 1 |
| Beamon, K | 1 |
| Synold, TW | 1 |
| Longmate, J | 1 |
| Slatkin, NE | 1 |
| Doroshow, JH | 1 |
| Forman, S | 1 |
| Margolin, K | 1 |
| Morgan, R | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Jones, RB | 3 |
| Stockerl-Goldstein, KE | 1 |
| Klein, J | 1 |
| Murphy, J | 1 |
| Blume, KG | 1 |
| Dansey, R | 1 |
| Martinez, C | 1 |
| Matthes, S | 1 |
| Nieto, Y | 1 |
| Mazeron, JJ | 1 |
| Manavis, J | 1 |
| Ambatzoglou, J | 1 |
| Wozniak, K | 1 |
| Kolacinska, A | 1 |
| Blasinska-Morawiec, M | 1 |
| Morawiec-Bajda, A | 1 |
| Morawiec, Z | 1 |
| Zadrozny, M | 1 |
| Blasiak, J | 1 |
| Yuhas, JM | 1 |
| Spellman, JM | 1 |
| Culo, F | 1 |
| Shpall, EJ | 3 |
| Stemmer, SM | 2 |
| Bearman, SI | 3 |
| Myers, S | 1 |
| Purdy, M | 1 |
| Hami, L | 2 |
| Franklin, WA | 2 |
| Shaw, L | 1 |
| Bonner, HS | 1 |
| Peters, WP | 1 |
| Bast, RC | 1 |
| McCulloch, W | 1 |
| Cagnoni, PJ | 1 |
| Ross, M | 1 |
| Capizzi, R | 1 |
| Schein, PS | 1 |
| Ramnath, N | 1 |
| LoRusso, P | 1 |
| Simon, M | 1 |
| Martino, S | 1 |
| Kusenda, Z | 1 |
| Kerger, J | 2 |
| Awada, A | 2 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Gelmon, K | 1 |
| Eisenhauer, E | 1 |
| Bryce, C | 1 |
| Tolcher, A | 1 |
| Mayer, L | 1 |
| Tomlinson, E | 1 |
| Zee, B | 1 |
| Blackstein, M | 1 |
| Tomiak, E | 1 |
| Yau, J | 1 |
| Batist, G | 1 |
| Fisher, B | 1 |
| Iglesias, J | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Prescott, LM | 1 |
| Gradishar, WJ | 1 |
| Stephenson, P | 1 |
| Glover, DJ | 1 |
| Neuberg, DS | 1 |
| Moore, MR | 1 |
| Windschitl, HE | 1 |
| Piel, I | 1 |
| Abeloff, MD | 1 |
| Kouroussis, C | 1 |
| Kakolyris, S | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Freyer, G | 1 |
| Hennebert, P | 1 |
| Gil, T | 1 |
| Selleslags, J | 1 |
| Brassinne, C | 1 |
| Piccart, M | 1 |
| de Valeriola, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel[NCT04995328] | 23 participants (Actual) | Interventional | 2021-08-03 | Completed | |||
| A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity[NCT00003624] | Phase 2 | 0 participants | Interventional | 1998-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amifostine anhydrous and Breast Neoplasms
| Article | Year |
|---|---|
Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Topics: Amifostine; Apoptosis; Breast Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Combined Modality T | 2002 |
12 trials available for amifostine anhydrous and Breast Neoplasms
| Article | Year |
|---|---|
Normal tissue radioprotection by amifostine via Warburg-type effects.
Topics: Adenosine Triphosphate; Amifostine; Animals; Basal Metabolism; Blood Glucose; Breast Neoplasms; Fema | 2016 |
Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine.
Topics: Amifostine; Antimutagenic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tu | 2010 |
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2003 |
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
Topics: Amifostine; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1993 |
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Combined Moda | 1994 |
Use of amifostine in bone marrow purging.
Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cyclophospham | 1996 |
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Mod | 1999 |
A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Disease Progression; Dr | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therap | 2002 |
18 other studies available for amifostine anhydrous and Breast Neoplasms
| Article | Year |
|---|---|
Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.
Topics: Amifostine; Animals; Breast Neoplasms; Female; Humans; Mammaplasty; Radiation Injuries; Radiation-Pr | 2020 |
Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Topics: Amifostine; Animals; Blood Pressure; Breast Neoplasms; Disease Models, Animal; DNA Damage; Dogs; Dru | 2019 |
Prophylactic amifostine prevents a pathologic vascular response in a murine model of expander-based breast reconstruction.
Topics: Amifostine; Angiography; Animals; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationsh | 2016 |
Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Topics: Adult; Aged; Amifostine; Breast Diseases; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; M | 2009 |
Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Breast Neoplasms; Case-Control Studies; Combined Modalit | 2013 |
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Topics: Alkaline Phosphatase; Amifostine; Antigens, Neoplasm; Biomarkers, Tumor; Breast; Breast Neoplasms; C | 2002 |
Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients.
Topics: Amifostine; Breast Neoplasms; fas Receptor; Female; Humans; Lymphocyte Subsets; Platelet Endothelial | 2003 |
Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha.
Topics: Amifostine; Animals; Blood Glucose; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tu | 2004 |
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Topics: Adult; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2004 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Breast; Breast Neoplasms; Cohort Studies; Combined M | 2006 |
The DNA-damaging potential of tamoxifen in breast cancer and normal cells.
Topics: Adult; Amifostine; Ascorbic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Comet Assay; DN | 2007 |
The role of WR-2721 in radiotherapy and/or chemotherapy.
Topics: Alkylating Agents; Amifostine; Animals; Breast Neoplasms; Cyclophosphamide; Humans; In Vitro Techniq | 1980 |
Amifostine shortens bone marrow recovery period in breast cancer patients.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation | 1995 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Mo | 1995 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |